Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of 626 in Healthy Adult Subjects
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-626 in healthy adult subjects after single subcutaneous injection.
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SSGJ-626 in Healthy Adult Subjects
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-12-02
Completion Date
2025-10
Last Updated
2024-12-10
Healthy Volunteers
Yes
Conditions
Interventions
626
Single subcutaneous injection
Placebo
Single subcutaneous injection
Locations (1)
Shanghai General Hospital
Shanghai, China